TScan Therapeutics (TCRX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Vikram Purohit from Morgan Stanley maintained a Buy rating ...

(RTTNews) - Shares of TScan Therapeutics, Inc. (TCRX), a clinical-stage biotechnology company specializing in T cell receptor-engineered therapies for cancer, are surging in premarket trading ...

Barclays analyst Peter Lawson assigned a Buy rating to TScan Therapeutics (TCRX – Research Report) today and set a price target of $14.00. The company’s shares closed yesterday at $3.08.